These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 24133278)

  • 1. Glycine transporter-1 inhibition promotes striatal axon sprouting via NMDA receptors in dopamine neurons.
    Schmitz Y; Castagna C; Mrejeru A; Lizardi-Ortiz JE; Klein Z; Lindsley CW; Sulzer D
    J Neurosci; 2013 Oct; 33(42):16778-89. PubMed ID: 24133278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat.
    Nash JE; Brotchie JM
    Mov Disord; 2002 May; 17(3):455-66. PubMed ID: 12112191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
    Oiwa Y; Yoshimura R; Nakai K; Itakura T
    Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Striatal dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors.
    Marti M; Mela F; Bianchi C; Beani L; Morari M
    J Neurochem; 2002 Nov; 83(3):635-44. PubMed ID: 12390525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease.
    Dunah AW; Wang Y; Yasuda RP; Kameyama K; Huganir RL; Wolfe BB; Standaert DG
    Mol Pharmacol; 2000 Feb; 57(2):342-52. PubMed ID: 10648644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits.
    Oh JD; Vaughan CL; Chase TN
    Brain Res; 1999 Mar; 821(2):433-42. PubMed ID: 10064831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VGluT2 Expression in Dopamine Neurons Contributes to Postlesional Striatal Reinnervation.
    Kouwenhoven WM; Fortin G; Penttinen AM; Florence C; Delignat-Lavaud B; Bourque MJ; Trimbuch T; Luppi MP; Salvail-Lacoste A; Legault P; Poulin JF; Rosenmund C; Awatramani R; Trudeau LÉ
    J Neurosci; 2020 Oct; 40(43):8262-8275. PubMed ID: 32928885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease.
    Rosenblad C; Martinez-Serrano A; Björklund A
    Neuroscience; 1998 Jan; 82(1):129-37. PubMed ID: 9483509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model.
    Rosenblad C; Kirik D; Björklund A
    Exp Neurol; 2000 Feb; 161(2):503-16. PubMed ID: 10686072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chondroitinase improves midbrain pathway reconstruction by transplanted dopamine progenitors in Parkinsonian mice.
    Kauhausen JA; Thompson LH; Parish CL
    Mol Cell Neurosci; 2015 Nov; 69():22-9. PubMed ID: 26463051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease.
    Calabresi P; Mercuri NB; Sancesario G; Bernardi G
    Brain; 1993 Apr; 116 ( Pt 2)():433-52. PubMed ID: 8096420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-methyl-D-aspartate receptor blockade attenuates D1 dopamine receptor modulation of neuronal activity in rat substantia nigra.
    Huang KX; Bergstrom DA; Ruskin DN; Walters JR
    Synapse; 1998 Sep; 30(1):18-29. PubMed ID: 9704877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32.
    Dunah AW; Sirianni AC; Fienberg AA; Bastia E; Schwarzschild MA; Standaert DG
    Mol Pharmacol; 2004 Jan; 65(1):121-9. PubMed ID: 14722243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hesperidin Ameliorates Anxiety-Depressive-Like Behavior in 6-OHDA Model of Parkinson's Disease by Regulating Striatal Cytokine and Neurotrophic Factors Levels and Dopaminergic Innervation Loss in the Striatum of Mice.
    Antunes MS; Cattelan Souza L; Ladd FVL; Ladd AABL; Moreira AL; Bortolotto VC; Silva MRP; Araújo SM; Prigol M; Nogueira CW; Boeira SP
    Mol Neurobiol; 2020 Jul; 57(7):3027-3041. PubMed ID: 32458386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methamphetamine induces fos expression in the striatum and the substantia nigra pars reticulata in a rat model of Parkinson's disease.
    Ishida Y; Todaka K; Kuwahara I; Ishizuka Y; Hashiguchi H; Nishimori T; Mitsuyama Y
    Brain Res; 1998 Oct; 809(1):107-14. PubMed ID: 9795171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutamate controls growth rate and branching of dopaminergic axons.
    Schmitz Y; Luccarelli J; Kim M; Wang M; Sulzer D
    J Neurosci; 2009 Sep; 29(38):11973-81. PubMed ID: 19776283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease.
    Nash JE; Brotchie JM
    J Neurosci; 2000 Oct; 20(20):7782-9. PubMed ID: 11027242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activin A protects midbrain neurons in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Stayte S; Rentsch P; Li KM; Vissel B
    PLoS One; 2015; 10(4):e0124325. PubMed ID: 25902062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular distribution of the NMDA receptor subunit NMDAR1 in fetal ventral mesencephalon transplants in the dopamine-depleted striatum of a rat.
    Todaka K; Ishida Y; Hashiguchi H; Nishimori T; Mitsuyama Y
    Exp Neurol; 1999 Dec; 160(2):394-401. PubMed ID: 10619556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fetal ventral mesencephalic grafts functionally reduce the dopamine D2 receptor supersensitivity in partially dopamine reinnervated host striatum.
    Strömberg I; Kehr J; Andbjer B; Fuxe K
    Exp Neurol; 2000 Jul; 164(1):154-65. PubMed ID: 10877926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.